Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 2, 2002, Pages 204-208

  Cloughesy, Timothy F ^a   Filka, Emese ^a   Nelson, Gillian ^a   Kabbinavar, Fairooz ^a   Friedman, Henry ^b   Miller, Langdon L ^c   Elfring, Gary L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

Author keywords

CPT 11; Irinotecan; Malignant glioma

Indexed keywords

ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ATROPINE; CARBAMAZEPINE; DEXAMETHASONE; ENZYME INDUCING AGENT; GABAPENTIN; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; LOPERAMIDE; LORAZEPAM; NITROSOUREA DERIVATIVE; ONDANSETRON; PHENYTOIN; PROCHLORPERAZINE; VALPROIC ACID;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SURVIVAL TIME; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS;

EID: 0036220269     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200204000-00022     Document Type: Article

References (21)

1. Chemotherapy for brain tumors
2. Clinical management of brain metastases
3. Palliative treatment of brain metastases
4. Outcomes and prognostic factors in recurrent glioma patient enrolled onto phase II clinical trials
5. Antileukemic activity of new camptothecin derivatives
6. Antitumor activity of newly synthesized, lactone ring-closed and water-soluble camptothecin derivative in mice
7. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors
8. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerse I
9. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
10. Phase I and pharmacokinetic trial of weekly CPT-11
11. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
12. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidinol]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts
13. Irinotecan treatment of adults with recurrent or malignant glioma
14. Irinotecan therapy in adults with recurrent or progressive malignant glioma
15. CPT-11: An original spectrum of clinical activity
16. Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11
17. Influence of age on the pharmacokinetics of irinotecan (CPT-11) and its metabolites, SN-38 and SN-38 glucuronide (SN-38G) in patients with previously treated colorectal cancer
18. Pharmacokinetics of irinotecan (CPT-11) in recurrent glioma patients: Result of an NCCTG phase II trial
19. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital
20. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors